These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 2119485)

  • 41. Myths and facts in end-stage renal disease treatment.
    Potter DJ
    Ariz Med; 1984 Feb; 41(2):107-8. PubMed ID: 6367713
    [No Abstract]   [Full Text] [Related]  

  • 42. The costs of renal services in Britain.
    Mallick NP
    Nephrol Dial Transplant; 1997; 12 Suppl 1():25-8. PubMed ID: 9075225
    [No Abstract]   [Full Text] [Related]  

  • 43. [The cost of treating patients with chronic kidney failure].
    Balakirev EM; Levitskiĭ ER
    Sov Zdravookhr; 1987; (5):25-7. PubMed ID: 3616733
    [No Abstract]   [Full Text] [Related]  

  • 44. Paying for expensive new technologies: Medicare's experiences with recombinant erythropoietin.
    Coster JM; Gianfrancesco F; Chuldzinski P
    Cancer Invest; 1991; 9(6):675-81. PubMed ID: 1747793
    [No Abstract]   [Full Text] [Related]  

  • 45. DUE uncovers lost opportunity for savings in laboratory costs.
    Orlando CP
    Am J Hosp Pharm; 1992 Mar; 49(3):561-2. PubMed ID: 1598920
    [No Abstract]   [Full Text] [Related]  

  • 46. Update to Epogen information in article on future drug expenditures.
    Evens PE
    Am J Health Syst Pharm; 1995 Jun; 52(12):1348-9. PubMed ID: 7656127
    [No Abstract]   [Full Text] [Related]  

  • 47. Conservative management of end-stage renal failure: masterly inactivity or benign neglect? See Smith et al., pp. c40-c46.
    Burns A
    Nephron Clin Pract; 2003; 95(2):c37-9. PubMed ID: 14610333
    [No Abstract]   [Full Text] [Related]  

  • 48. Viewpoint.....short or long term savings? Will prohibitive costs make dialysis a transient theory?
    Litchfield WE
    Nephrol Nurse; 1979; 1(1):33-5. PubMed ID: 255773
    [No Abstract]   [Full Text] [Related]  

  • 49. Letter: Cost-benefit analysis of long-term haemodialysis for chronic renal failure.
    Roberts JA
    Br Med J; 1975 Jul; 3(5977):230. PubMed ID: 1148750
    [No Abstract]   [Full Text] [Related]  

  • 50. Picking up the tab for erythropoietin.
    BMJ; 1991 Mar; 302(6776):592. PubMed ID: 2021730
    [No Abstract]   [Full Text] [Related]  

  • 51. Battery energy storage sizing when time of use pricing is applied.
    Carpinelli G; Khormali S; Mottola F; Proto D
    ScientificWorldJournal; 2014; 2014():906284. PubMed ID: 25295309
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost analysis and the clinical nurse specialist.
    Lipetzky PW
    Nurs Manage; 1990 Aug; 21(8):25, 28. PubMed ID: 2116609
    [No Abstract]   [Full Text] [Related]  

  • 53. Pharmacogenomic testing: the cost factor.
    Wedlund PJ; de Leon J
    Pharmacogenomics J; 2001; 1(3):171-4. PubMed ID: 11908752
    [No Abstract]   [Full Text] [Related]  

  • 54. Comment on "Cost analysis and sociocultural profile of kidney patients. Impact of the treatment method".
    Arrieta-Lezama J; Selgas-Gutiérrez R
    Nefrologia; 2015; 35(1):115-6. PubMed ID: 25611840
    [No Abstract]   [Full Text] [Related]  

  • 55. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations.
    Collins AJ
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 2():ii2-6. PubMed ID: 12819293
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Costs of chronic dialysis in a public hospital: myths and realities].
    Lamas J; Alonso M; Saavedra J; García-Trío G; Rionda M; Ameijeiras M
    Nefrologia; 2001; 21(3):283-94. PubMed ID: 11471309
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recombinant erythropoietin. The effect of the marketplace on socialized patient care.
    Besarab A; Erslev AJ
    ASAIO J; 1993; 39(2):85-6. PubMed ID: 8324265
    [No Abstract]   [Full Text] [Related]  

  • 58. [Comparative aspects of the cost/benefits ratio in dialysis-transplant].
    Guzzanti E; Picca S
    Minerva Chir; 1989 Feb; 44(4):793-800. PubMed ID: 2497406
    [No Abstract]   [Full Text] [Related]  

  • 59. EPO--one year later. Part II. Balancing the costs and benefits.
    Blagg C
    Nephrol News Issues; 1990 Jun; 4(6):22, 38. PubMed ID: 2119485
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.